[go: up one dir, main page]

NO20000406L - Metoder til forbehandling av individer med hyperlipidemi med et flushinhiberende middel i forkant av nikotinsyreterapi - Google Patents

Metoder til forbehandling av individer med hyperlipidemi med et flushinhiberende middel i forkant av nikotinsyreterapi

Info

Publication number
NO20000406L
NO20000406L NO20000406A NO20000406A NO20000406L NO 20000406 L NO20000406 L NO 20000406L NO 20000406 A NO20000406 A NO 20000406A NO 20000406 A NO20000406 A NO 20000406A NO 20000406 L NO20000406 L NO 20000406L
Authority
NO
Norway
Prior art keywords
nicotinic acid
approx
therapy
pretreatment
individuals
Prior art date
Application number
NO20000406A
Other languages
English (en)
Other versions
NO20000406D0 (no
Inventor
Eugenio A Cefali
Original Assignee
Kos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25418033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20000406(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kos Pharma Inc filed Critical Kos Pharma Inc
Publication of NO20000406D0 publication Critical patent/NO20000406D0/no
Publication of NO20000406L publication Critical patent/NO20000406L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelse vedrører forhåndsbehandling av individer med en effektiv mengde av et rødmingsinhiberende agens for et tidsrom som er tilstrekkelig forut for oppstart av nikotinsyreterapi med enkeltstående daglig dose til reduksjon av nikotinsyrens mulighet for å indusere rødmingsreaksjoner i slike individer i løpet av nikotinsyreterapi. I samsvar med den foreliggende oppfinnelse, administreres de rødmingsinhiberende agenser oralt en til fire ganger om dagen, og fortrinnsvis en til to ganger per dag, i løpet av ca. 7 til ca. 14 dager forut for oppstart av nikotinsyreterapien. Eksempler på rødmingsinhiberende agenser inklu- derer ikke stereodale anti-inflammatoriskc agenser. Aspirin er et foretrukket rødmingsinhi- berende agens og kan administreres oralt i daglige doser på mellom ca. SOmg til ca. lOOOmg, og fortrinnsvis mellom ca. SOmg og ca. 650mg, og enda heller mellom ca.'80mg og ca. 325mg, i løpet av forhåndsbehandlingsperioden. Også i overensstemmelse med den forelig- gende oppfinnelse, kan forhåndsbehandlingsterapien fortsettes under og administreres ledsa- gende med nikotinsyreterapien, hvori nikotinsyren med fordel administreres en gang per dag som en enkeltdose i løpet av kveldstimene eller før eller ved leggetid. Nikotinsyren kan ad- ministreres alene eller i kombinasjon med HMG-CoA reduktaseinhibitorer så vel som andre lipidendrende agenser, i likhet med kolestyramin og colestipol.
NO20000406A 1997-07-31 2000-01-27 Metoder til forbehandling av individer med hyperlipidemi med et flushinhiberende middel i forkant av nikotinsyreterapi NO20000406L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/903,755 US6469035B1 (en) 1997-07-31 1997-07-31 Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
PCT/US1998/015987 WO1999006052A1 (en) 1997-07-31 1998-07-31 Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid

Publications (2)

Publication Number Publication Date
NO20000406D0 NO20000406D0 (no) 2000-01-27
NO20000406L true NO20000406L (no) 2000-03-20

Family

ID=25418033

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000406A NO20000406L (no) 1997-07-31 2000-01-27 Metoder til forbehandling av individer med hyperlipidemi med et flushinhiberende middel i forkant av nikotinsyreterapi

Country Status (6)

Country Link
US (1) US6469035B1 (no)
EP (1) EP0999844A1 (no)
AU (1) AU8605298A (no)
CA (1) CA2297756C (no)
NO (1) NO20000406L (no)
WO (1) WO1999006052A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US20040018628A1 (en) * 2001-08-31 2004-01-29 Burd John F. Integrated assay for organ function, drug and / or one or more metabolites
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7128806B2 (en) * 2003-10-21 2006-10-31 Applied Materials, Inc. Mask etch processing apparatus
US20080058292A1 (en) * 2003-10-29 2008-03-06 Raif Tawakol Method for increasing HDL and HDL-2b levels
EP1684704A2 (en) * 2003-10-29 2006-08-02 Raif M. Tawakol Compositions and methods for increasing hdl and hdl-2b levels
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
ES2383822T3 (es) * 2005-07-11 2012-06-26 Cortria Corporation Formulaciones para el tratamiento de anomalías de lipoproteínas que comprenden una estatina y un derivado de metilnicotinamida
US20070105793A1 (en) * 2005-11-04 2007-05-10 Curt Hendrix Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
PL2026651T3 (pl) * 2006-03-08 2013-06-28 Cortria Corp Terapia kombinowana za pomocą nieselektywnych inhibitorów COX dla zapobiegania uszkodzeń żołądka związanych z COX
WO2008091338A1 (en) * 2007-01-23 2008-07-31 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
CN101686674A (zh) * 2007-03-01 2010-03-31 康考斯保健科学有限责任公司 肌醇烟酸酯的异构体及其用途
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
WO2008127893A1 (en) * 2007-04-04 2008-10-23 Hight H Thomas Niacin-based pharmaceutical compositions
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
WO2009022821A2 (en) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
WO2009033072A1 (en) * 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
US20090130208A1 (en) * 2007-11-21 2009-05-21 Capricorn Pharma Inc. Modified release niacin formulations
BRPI0912842A8 (pt) * 2008-05-20 2019-01-29 Cerenis Therapeutics Holding composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
US20110086074A1 (en) * 2008-06-02 2011-04-14 Dr. Reddy's Laboratories Ltd. Combinations of niacin and an oxicam
WO2009149058A2 (en) * 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
WO2010010579A1 (en) * 2008-07-19 2010-01-28 Lupin Limited Multiple unit dosage form of niacin
JP2012514652A (ja) * 2009-01-08 2012-06-28 アンセラ・ファーマシューティカルズ・インコーポレイテッド 心血管疾患および脂質異常症を治療するための分泌ホスホリパーゼａ２（ｓｐｌａ２）インヒビターとナイアシン薬との組成物および方法
GEP20146015B (en) 2009-06-25 2014-01-27 Tetra Sia Novel acetylsalicylic acid salts
US8834858B2 (en) * 2010-07-02 2014-09-16 Solvotrin Therapeutics Ltd. Treatment for dyslipidemia
JP5726481B2 (ja) * 2010-10-29 2015-06-03 日本精化株式会社 ヒドロキシニコチン酸又はその誘導体を含有する化粧料又は皮膚外用剤
US9226891B2 (en) 2011-10-28 2016-01-05 Vitalis Llc Anti-flush compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1704M (fr) * 1961-12-19 1963-02-18 Aec Chim Organ Biolog Médicament anti-allergique et anti-histaminique a base de β-alanine.
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
DE2722113A1 (de) * 1969-07-17 1978-11-02 Christian Brunnengraeber Chem Therapeutisches mittel
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
US4911917A (en) * 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
WO1996032942A1 (en) * 1995-04-19 1996-10-24 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs

Also Published As

Publication number Publication date
WO1999006052A1 (en) 1999-02-11
EP0999844A1 (en) 2000-05-17
AU8605298A (en) 1999-02-22
CA2297756A1 (en) 1999-02-11
NO20000406D0 (no) 2000-01-27
CA2297756C (en) 2008-04-29
WO1999006052A9 (en) 1999-04-29
US6469035B1 (en) 2002-10-22

Similar Documents

Publication Publication Date Title
NO20000406L (no) Metoder til forbehandling av individer med hyperlipidemi med et flushinhiberende middel i forkant av nikotinsyreterapi
NO20074316L (no) Utvidet frigjoringsformulering av levetiracetam
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
FI951454A0 (fi) 1-(2-oksoasetyyli)piperidiini-2-karboksyylihappojohdannaiset monille lääkkeille resistenttien syöpäsolujen herkistäjinä
WO2000013684A3 (en) Pharmaceutical composition and method for treatment of inflammation
DK0828724T3 (da) 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DK0853083T3 (da) Pyridylfuran- og piridylthiophenforbindelser og farmaceutisk anvendelse deraf
DE69529690D1 (de) Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
NO20000407L (no) Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyre samt fremgangsmõter til behandling av hyperlipidemi
DK0888111T3 (da) Modified-release-dosispræparat med multiple enheder
GEP20053619B (en) Pyrazole Derivatives for Treating HIV
BG103000A (en) Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases
NO994671L (no) Aryl- eller heteroarylsulfonamid-substituerte hydroksamsyrederivater, fremgangsmåte til fremstilling derav og deres anvendelse som farmasöytika
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
CA2301742A1 (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
KR910700045A (ko) Hiv 감염 관련 질병의 치료
Alexanian et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
WO1996022774A2 (en) Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins
JPH02233611A (ja) ＨＭＧ―ＣｏＡレダクターゼ阻害剤と併用される補酵素Ｑ↓１↓０
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
BR0211936A (pt) Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application